Stay updated with breaking news from Sangui biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Sangui BioTech International I, Increase in sales in the first quarter of 121% - Highest quarterly sales in the company's history
17.05.2022 - Issuer: Sangui BioTech International Inc. / Key word(s): 9 Month figures Sangui BioTech International Inc.: - Increase in sales in the first nine months of the year - Further reduction of the operating loss 17.05.2022 / 08:36 The issuer is solely ...
Investegate announcements from Sangui BioTech International I, Significant increase in sales in the first half of the year - Further reduction of the operating loss
Investegate |Sangui BioTech International I Announcements | Sangui BioTech International I: - Sales of USD 65,582 in fiscal year 2021 investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Sangui BioTech International Inc.: - Granulox(R) - Follow up 11.05.2021 / 11:05 Sangui BioTech: - Granulox(R) - Follow up Hamburg, May, 11 2021: With this letter we would like to briefly summarize the events since the acquisition of Sastomed GmbH by the Mölnlycke Health Care Group and point out the latest developments in the Granulox(R) wound spray. The acquisition of SastoMed GmbH by the Mölnlycke Health Care Group at the end of June 2018 was the starting point for an extensive integration and reorganization program with the target of increasing the market potential of the Granulox(R) wound spray. In addition to adapting the logistical processes, these measures also included legal changes. With the merger of Sastomed GmbH in 2020 with its parent company Mölnylcke Health Care GmbH, Mölnylcke Health Care GmbH is now the contractional licensee of Granulox(R). In addition, extensive and sometimes lengthy restructuring process was carried out in the sales area. The integration of Granulox(R) sales into the sales structure of the Mölnlycke Health Care Group required the reorganization of the partnerships SastoMed GmbH previously entered into in the individual sales territories until 2018. Accordingly, there were temporary slowdown in sales growth in these territories.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;